Stroke patients have a new hope for arm rehabilitation thanks to a team from UH. Photo courtesy of UH

Almost 800,000 people in the United States suffer from a stroke annually — and the affliction affects each patient differently. One University of Houston researcher has created a device that greatly improves the lives of patients whose stroke affected motor skills.

UH engineering professor Jose Luis Contreras-Vidal developed a next-generation robotic arm that can be controlled by the user's brainwaves. The portable device uses a brain-computer interface (BCI) developed by Contreras-Vidal. Stroke patient Oswald Reedus, 66, is the first person to use a device of this kind.

Reedus lost the use of his left arm following a stroke that also caused aphasia, or difficulty speaking. While he's been able to recover his ability to speak clearly, the new exoskeleton will help rehabilitate his arm.

When strapped into the noninvasive device, the user's brain activity is translated into motor commands to power upper-limb robotics. As patients like Reedus use the device, more data is collected to improve the experience.

“If I can pass along anything to help a stroke person’s life, I will do it. For me it’s my purpose in life now,” says Reedus in a news release from UH. His mother and younger brother both died of strokes, and Reedus is set on helping the device that can help other stroke patients recover.

Contreras-Vidal, a Hugh Roy and Lillie Cranz Cullen distinguished professor, has led his device from ideation to in-home use, like with Reedus, as well as clinical trials at TIRR Memorial Hermann. The project is funded in part from an $813,999 grant from the National Science Foundation’s newly created Division of Translational Impacts.

"Our project addresses a pressing need for accessible, safe, and effective stroke rehabilitation devices for in-clinic and at-home use for sustainable long-term therapy, a global market size expected to currently be $31 billion," Contreras-Vidal says in the release. "Unfortunately, current devices fail to engage the patients, are hard to match to their needs and capabilities, are costly to use and maintain, or are limited to clinical settings."

Dr. Gerard E. Francisco, chief medical officer and director of the Neuro Recovery Research Center at TIRR Memorial Hermann, is leading the clinical trials for the device. He's also chair and professor in the Department of Physical Medicine and Rehabilitation at McGovern Medical School at UTHealth Houston. He explains that TIRR's partnership with engineering schools such as the Cullen College of Engineering at UH and others around the nation is strategic.

“This is truly exciting because what we know now is there are so many ways we can induce neuroplasticity or how we can boost recovery,” says Francisco in the release. “That collaboration is going to give birth to many of these groundbreaking technologies and innovations we can offer our patients.”

Both parts of the device — a part that attaches to the patient's head and a part affixed to their arm — are noninvasive. Photo courtesy of UH

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.